Finding new treatments for Merkel cell carcinoma
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment
This study is looking for new ways to treat Merkel cell carcinoma, a tough skin cancer, by testing a drug called fimepinostat to see if it can work better on its own or with other immune treatments, helping patients who have limited options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern California Inst for Res/educ NIH-funded |
| Lab location | 1 site (Long Beach, UNITED STATES) |
| Project ID | NIH-10880444 on NIH RePORTER |
What this research studies
This research focuses on Merkel cell carcinoma (MCC), a serious skin cancer with limited treatment options and a low survival rate. The team aims to identify new therapies that can enhance the effectiveness of existing immune checkpoint inhibitors or provide alternatives for patients who cannot use these treatments. They will use laboratory-established MCC cell lines and conduct extensive drug screening to evaluate the efficacy of a specific drug, fimepinostat, both alone and in combination with immune therapies. The goal is to understand how this drug works against MCC and how it can improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with advanced Merkel cell carcinoma, especially those who are ineligible for immune checkpoint inhibitors.
Not a fit: Patients with early-stage Merkel cell carcinoma or those who are already responding well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with Merkel cell carcinoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, suggesting that this approach may yield beneficial results for Merkel cell carcinoma as well.
Where this research is happening
Long Beach, UNITED STATES
- Southern California Inst for Res/educ — Long Beach, United States (Active)
Researchers
- Principal investigator: Gao, Ling — Southern California Inst for Res/educ
- Study coordinator: Gao, Ling
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.